214 related articles for article (PubMed ID: 18477625)
1. Current guidelines and their recommendations for prolactin monitoring in psychosis.
Citrome L
J Psychopharmacol; 2008 Mar; 22(2 Suppl):90-7. PubMed ID: 18477625
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotics and hyperprolactinaemia: clinical recommendations.
Peveler RC; Branford D; Citrome L; Fitzgerald P; Harvey PW; Holt RI; Howard L; Kohen D; Jones I; O'Keane V; Pariente CM; Pendlebury J; Smith SM; Yeomans D
J Psychopharmacol; 2008 Mar; 22(2 Suppl):98-103. PubMed ID: 18477626
[TBL] [Abstract][Full Text] [Related]
3. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
4. [Hyperprolactinemia in mentally ill patients].
Carvalho MM; Góis C
Acta Med Port; 2011; 24(6):1005-12. PubMed ID: 22713195
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic-induced hyperprolactinemia.
Bostwick JR; Guthrie SK; Ellingrod VL
Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
[TBL] [Abstract][Full Text] [Related]
6. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
[TBL] [Abstract][Full Text] [Related]
7. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.
Maguire GA
J Clin Psychiatry; 2002; 63 Suppl 4():56-62. PubMed ID: 11913677
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research.
Grigg J; Worsley R; Thew C; Gurvich C; Thomas N; Kulkarni J
Psychopharmacology (Berl); 2017 Nov; 234(22):3279-3297. PubMed ID: 28889207
[TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Antipsychotic-Induced Hyperprolactinemia.
Wong-Anuchit C
Perspect Psychiatr Care; 2016 Apr; 52(2):145-52. PubMed ID: 25772527
[TBL] [Abstract][Full Text] [Related]
10. Hyperprolactinemia associated with psychotropics--a review.
Madhusoodanan S; Parida S; Jimenez C
Hum Psychopharmacol; 2010; 25(4):281-97. PubMed ID: 20521318
[TBL] [Abstract][Full Text] [Related]
11. Medication-induced hyperprolactinemia.
Molitch ME
Mayo Clin Proc; 2005 Aug; 80(8):1050-7. PubMed ID: 16092584
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey.
Johnsen E; Kroken RA; Abaza M; Olberg H; Jørgensen HA
J Clin Psychopharmacol; 2008 Dec; 28(6):686-90. PubMed ID: 19011438
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
Byerly M; Suppes T; Tran QV; Baker RA
J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
[TBL] [Abstract][Full Text] [Related]
14. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
Holt RI
J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
[TBL] [Abstract][Full Text] [Related]
15. Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder.
Walters J; Jones I
J Psychopharmacol; 2008 Mar; 22(2 Suppl):82-9. PubMed ID: 18477624
[TBL] [Abstract][Full Text] [Related]
16. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option.
Rusgis MM; Alabbasi AY; Nelson LA
Am J Health Syst Pharm; 2021 May; 78(10):862-871. PubMed ID: 33954421
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotics and osteoporosis: current awareness and practice in primary care.
Jones E
Br J Gen Pract; 2014 Nov; 64(628):562-3. PubMed ID: 25348972
[No Abstract] [Full Text] [Related]
18. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
Hummer M; Huber J
Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
[TBL] [Abstract][Full Text] [Related]
20. Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review.
Froes Brandao D; Strasser-Weippl K; Goss PE
Cancer; 2016 Jan; 122(2):184-8. PubMed ID: 26457577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
